But experts not only eye-roll this sort of speak as regular Muskian hoopla but declare that it deliberately ignores hugely unique issues not found in any of his other firms. Wexler and others Be aware that moral and publicity pitfalls, the slow pace of trials, the scientific uncertainty and even a 14-yr-outdated competitor named Blackrock Neurotech